Trial Profile
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen
- Indications Advanced breast cancer; Bone metastases; Carcinoma
- Focus Therapeutic Use
- Acronyms ASPIRE
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 03 May 2023 Planned End Date changed from 10 Aug 2023 to 30 Dec 2023.
- 03 May 2023 Planned primary completion date changed from 10 Aug 2023 to 30 Dec 2023.